D. DeRyckere

发表

Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

S. Frye, B. Hendriks, P. Harari, 2015, Molecular Cancer Therapeutics.

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission

Jennifer Schlegel, D. DeRyckere, D. Graham, 2013, Journal of Hematology & Oncology.

E2F1 and E2F2 Are Differentially Required for Homeostasis-Driven and Antigen-Induced T Cell Proliferation In Vivo1

J. DeGregori, D. DeRyckere, 2005, The Journal of Immunology.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

S. Frye, H. Earp, A. Hill, 2015, Oncotarget.

UNC1062, a new and potent Mer inhibitor.

S. Frye, W. Janzen, H. Earp, 2013, European journal of medicinal chemistry.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection.

Y. Wan, J. DeGregori, D. DeRyckere, 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Melissa A. Sandahl, Kristen M. Jacobsen, H. Earp, 2013, The Journal of clinical investigation.

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members

S. Frye, H. Earp, Xiaodong Wang, 2018, Clinical Cancer Research.

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Kristen M. Jacobsen, S. Frye, J. Tyner, 2016, Clinical Cancer Research.

Single Cell RNA Sequencing Driven Characterization of Pediatric Mixed Phenotype Acute Leukemia

D. Wechsler, D. DeRyckere, D. Graham, 2022, bioRxiv.

Vivo Regulation During Negative Selection In Characterization of Transcriptional

J. DeGregori, D. DeRyckere, D. Mann, 2003 .

The MERTK / FLT 3 inhibitor MRX-2843 overcomes resistance-conferring FLT 3 mutations in acute myeloid leukemia

S. Frye, C. Jordan, Catherine C. Smith, 2018 .

The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises

D. DeRyckere, D. Graham, K. Minson, 2017, Journal of cell signaling.

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

S. Frye, H. Earp, C. Jordan, 2016, JCI insight.

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

S. Frye, T. Owonikoko, S. Ramalingam, 2022, The Journal of clinical investigation.

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia

D. Wechsler, M. Bhasin, Bhakti Dwivedi, 2021, Nature communications.

Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia

Christopher D. Scharer, M. Rupji, Bhakti Dwivedi, 2022, Nature communications.

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Kristen M. Jacobsen, S. Frye, H. Earp, 2018, JCI insight.

T Cell Proliferation In Vivo Antigen-Induced for Homeostasis-Driven and E2F1 and E2F2 Are Differentially Required

J. DeGregori, D. DeRyckere, 2005 .

BPTF Regulates Growth of Adult and Pediatric High-Grade Glioma through the MYC Pathway

Kristen L Jones, K. Ligon, N. Serkova, 2019, Oncogene.

Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.

S. Frye, D. Drewry, Yuewei Zhang, 2018, Journal of medicinal chemistry.

MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

D. DeRyckere, D. Graham, Diana M Fridlyand, 2020, Pharmacology & therapeutics.

The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

K. Davies, H. Earp, H. Earp, 2014, Nature Reviews Cancer.

Targeting the TAM Receptors in Leukemia

H. Earp, H. Earp, D. DeRyckere, 2016, Cancers.

Characterization of Transcriptional Regulation During Negative Selection In Vivo1

J. DeGregori, D. DeRyckere, D. Mann, 2003, The Journal of Immunology.

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents

D. DeRyckere, L. Gore, M. Macy, 2012, Investigational New Drugs.

Risk-associated alterations in marrow T cells in pediatric leukemia

Melissa L. Kemp, P. Qiu, M. Dhodapkar, 2020, JCI insight.

Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia

Christopher D. Scharer, M. Rupji, Bhakti Dwivedi, 2022, Nature Communications.

Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer

W. Franklin, A. Baron, L. Heasley, 2012, Oncogene.

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

Melissa L. Kemp, W. Lam, H. Fu, 2022, bioRxiv.

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

S. Frye, J. Tyner, H. Earp, 2021, Cancers.

Identification and characterization of transcription factor target genes using gene-targeted mice.

J. DeGregori, D. DeRyckere, 2002, Methods.

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

H. Earp, D. DeRyckere, D. Graham, 2021, Cancers.

LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia

Kristen M. Jacobsen, A. Tan, H. Earp, 2013 .

Keypoints

Kristen M. Jacobsen, A. Tan, H. Earp, 2019, Encyclopedia of Biometrics.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Kristen M. Jacobsen, D. DeRyckere, D. Graham, 2009, Blood.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia

D. DeRyckere, D. Graham, S. Christoph, 2013, Blood Cancer Journal.

Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase

L. Meltesen, A. Anwar, G. Johnson, 2006, Oncogene.

Abstract 240: MERTK inhibition induces an anti-leukemia dendritic cell - T cell axis while TYRO3 inhibition protects through a separate mechanism

S. Frye, Xiaodong Wang, H. Earp, 2022, Cancer Research.

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

D. Newton, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.

D. DeRyckere, D. Graham, S. Christoph, 2013, Journal of visualized experiments : JoVE.

Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies

D. DeRyckere, D. Graham, R. Summers, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

The Emerging Role of TYRO3 as a Therapeutic Target in Cancer

Xiaodong Wang, D. DeRyckere, D. Graham, 2018, Cancers.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

A Common Case of Cell Line Misidentification

Kristen M. Jacobsen, D. DeRyckere, D. Graham, 2014 .

The MERTK Signalling Pathway in Cancer

A. Hill, D. DeRyckere, D. Graham, 2015 .

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

S. Frye, S. Eckhardt, J. Tentler, 2018, Molecular Cancer Therapeutics.

Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations

N. Serkova, J. DeGregori, A. Hill, 2014, Clinical Cancer Research.

UNC5293, a potent, orally available and highly MERTK-selective inhibitor.

S. Frye, Xiaodong Wang, H. Earp, 2021, European journal of medicinal chemistry.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme

S. Frye, M. Varella‐Garcia, J. Kowalski, 2016, PloS one.

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

K. Davies, H. Earp, C. Cummings, 2014, OncoTarget.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus

D. DeRyckere, D. Graham, J. Schlegel, 2012, PloS one.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

S. Frye, W. Janzen, M. Machius, 2012, ACS medicinal chemistry letters.

Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Amy Lynnette Van Deusen, S. Frye, W. Janzen, 2012 .

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

S. Frye, P. Harari, K. Davies, 2018, Molecular Cancer Therapeutics.

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

H. Fu, Yuhong Du, S. Moore, 2023, bioRxiv.

Data-driven construction of anti-tumor agents with controlled polypharmacology.

Laura E. Herring, S. Frye, M. Miley, 2019, Journal of the American Chemical Society.

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

S. Frye, H. Earp, A. Hill, 2016 .

Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

S. Frye, T. P. Newton, H. Earp, 2014 .

Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening

Andrés J. García, E. Botchwey, S. Thomas, 2022, Advanced materials.

Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling

M. Bhasin, Bhakti Dwivedi, D. DeRyckere, 2020 .

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

S. Frye, X. Wang, H. Earp, 2018, Journal of thrombosis and haemostasis : JTH.

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

S. Frye, W. Janzen, H. Earp, 2013, Molecular Cancer Therapeutics.

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia

D. DeRyckere, K. Dhodapkar, S. Castellino, 2022, Journal for ImmunoTherapy of Cancer.

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

S. Frye, M. Machius, M. Miley, 2016, ACS medicinal chemistry letters.

Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma

David B. Darr, N. Sharpless, S. Frye, 2014 .

Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia

S. Frye, W. Janzen, H. Earp, 2014 .

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

N. Popitsch, H. Kohrt, R. Sullivan, 2013, Clinical Cancer Research.

Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.

Melissa L. Kemp, W. Lam, H. Fu, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and ex vivo data

E. Crowgey, A. Marsh, D. DeRyckere, 2023, Bioinformatics advances.

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis

D. DeRyckere, D. Graham, S. Castellino, 2023, Scientific reports.

TAM family kinases as therapeutic targets at the interface of cancer and immunity

H. Earp, D. DeRyckere, D. Graham, 2023, Nature Reviews Clinical Oncology.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

UNC 569 , a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo

S. Frye, W. Janzen, H. Earp, 2013 .

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML

Xiaodong Wang, Yuhong Du, D. DeRyckere, 2023, Pharmaceutical Research.

Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations

N. Serkova, J. DeGregori, A. Hill, 2014, Clinical Cancer Research.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Melissa A. Sandahl, Kristen M. Jacobsen, H. Earp, 2013, The Journal of clinical investigation.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, M. Machius, M. Miley, 2013, Journal of medicinal chemistry.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

TITLE: Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

S. Frye, Xiaodong Wang, S. Eckhardt, 2018 .

Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia

D. DeRyckere, Hope L. Mumme, Sunil S. Raikar, 2023, Genome Medicine.

Lymphoblastic Leukemia/Lymphoma in Mice Overexpressing the Mer Receptor Tyrosine Kinase.

A. Anwar, D. DeRyckere, D. Graham, 2005 .

Erratum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, D. DeRyckere, 2016, Oncogene.